D E Rathkopf1, M R Smith2, C J Ryan3, W R Berry4, N D Shore5, G Liu6, C S Higano7, J J Alumkal8, R Hauke9, R F Tutrone10, M Saleh11, E Chow Maneval12, S Thomas13, D S Ricci13, M K Yu14, C J de Boer15, A Trinh14, T Kheoh16, R Bandekar13, H I Scher1, E S Antonarakis17. 1. Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York. 2. Massachusetts General Hospital and Harvard Medical School, Boston. 3. UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco. 4. Cancer Centers of North Carolina, Raleigh. 5. Carolina Urologic Research Center, Myrtle Beach. 6. University of Wisconsin Carbone Cancer Center, Madison. 7. University of Washington, Fred Hutchinson Cancer Research Center, Seattle. 8. Knight Cancer Institute, Oregon Health & Science University, Portland. 9. Nebraska Cancer Specialists, Omaha. 10. Chesapeake Urologic Research Associates, Baltimore. 11. University of Alabama Comprehensive Cancer Center, Birmingham. 12. Aragon Pharmaceuticals, San Diego. 13. Janssen Research & Development, Spring House. 14. Janssen Research & Development, Los Angeles. 15. Janssen Biologics, B. V., Leiden, the Netherlands. 16. Janssen Research & Development, San Diego. 17. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, USA.
Abstract
BACKGROUND: Mutations in the androgen receptor (AR) ligand-binding domain (LBD), such as F877L and T878A, have been associated with resistance to next-generation AR-directed therapies. ARN-509-001 was a phase I/II study that evaluated apalutamide activity in castration-resistant prostate cancer (CRPC). Here, we evaluated the type and frequency of 11 relevant AR-LBD mutations in apalutamide-treated CRPC patients. PATIENTS AND METHODS: Blood samples from men with nonmetastatic CRPC (nmCRPC) and metastatic CRPC (mCRPC) pre- or post-abiraterone acetate and prednisone (AAP) treatment (≥6 months' exposure) were evaluated at baseline and disease progression in trial ARN-509-001. Mutations were detected in circulating tumor DNA using a digital polymerase chain reaction-based method known as BEAMing (beads, emulsification, amplification and magnetics) (Sysmex Inostics' GmbH). RESULTS: Of the 97 total patients, 51 had nmCRPC, 25 had AAP-naïve mCRPC, and 21 had post-AAP mCRPC. Ninety-three were assessable for the mutation analysis at baseline and 82 of the 93 at progression. The overall frequency of detected AR mutations at baseline was 7/93 (7.5%) and at progression was 6/82 (7.3%). Three of the 82 (3.7%) mCRPC patients (2 AAP-naïve and 1 post-AAP) acquired AR F877L during apalutamide treatment. At baseline, 3 of the 93 (3.2%) post-AAP patients had detectable AR T878A, which was lost after apalutamide treatment in 1 patient who continued apalutamide treatment for 12 months. CONCLUSIONS: The overall frequency of detected mutations at baseline (7.5%) and progression (7.3%) using the sensitive BEAMing assay was low, suggesting that, based on this assay, AR-LBD mutations such as F877L and T878A are not common contributors to de novo or acquired resistance to apalutamide. CLINICALTRIALS.GOV IDENTIFIER: NCT01171898.
BACKGROUND: Mutations in the androgen receptor (AR) ligand-binding domain (LBD), such as F877L and T878A, have been associated with resistance to next-generation AR-directed therapies. ARN-509-001 was a phase I/II study that evaluated apalutamide activity in castration-resistant prostate cancer (CRPC). Here, we evaluated the type and frequency of 11 relevant AR-LBD mutations in apalutamide-treated CRPC patients. PATIENTS AND METHODS: Blood samples from men with nonmetastatic CRPC (nmCRPC) and metastatic CRPC (mCRPC) pre- or post-abiraterone acetate and prednisone (AAP) treatment (≥6 months' exposure) were evaluated at baseline and disease progression in trial ARN-509-001. Mutations were detected in circulating tumor DNA using a digital polymerase chain reaction-based method known as BEAMing (beads, emulsification, amplification and magnetics) (Sysmex Inostics' GmbH). RESULTS: Of the 97 total patients, 51 had nmCRPC, 25 had AAP-naïve mCRPC, and 21 had post-AAP mCRPC. Ninety-three were assessable for the mutation analysis at baseline and 82 of the 93 at progression. The overall frequency of detected AR mutations at baseline was 7/93 (7.5%) and at progression was 6/82 (7.3%). Three of the 82 (3.7%) mCRPC patients (2 AAP-naïve and 1 post-AAP) acquired AR F877L during apalutamide treatment. At baseline, 3 of the 93 (3.2%) post-AAP patients had detectable AR T878A, which was lost after apalutamide treatment in 1 patient who continued apalutamide treatment for 12 months. CONCLUSIONS: The overall frequency of detected mutations at baseline (7.5%) and progression (7.3%) using the sensitive BEAMing assay was low, suggesting that, based on this assay, AR-LBD mutations such as F877L and T878A are not common contributors to de novo or acquired resistance to apalutamide. CLINICALTRIALS.GOV IDENTIFIER: NCT01171898.
Authors: Bruce Gottlieb; Lenore K Beitel; Abbesha Nadarajah; Miltiadis Paliouras; Mark Trifiro Journal: Hum Mutat Date: 2012-03-13 Impact factor: 4.878
Authors: Klaus Brasso; Frederik B Thomsen; Andres J Schrader; Sebastian C Schmid; David Lorente; Margitta Retz; Axel S Merseburger; Christoph A von Klot; Martin Boegemann; Johann de Bono Journal: Eur Urol Date: 2014-08-06 Impact factor: 20.096
Authors: Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers Journal: Nat Med Date: 2003-12-21 Impact factor: 53.440
Authors: Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Manav Korpal; Joshua M Korn; Xueliang Gao; Daniel P Rakiec; David A Ruddy; Shivang Doshi; Jing Yuan; Steve G Kovats; Sunkyu Kim; Vesselina G Cooke; John E Monahan; Frank Stegmeier; Thomas M Roberts; William R Sellers; Wenlai Zhou; Ping Zhu Journal: Cancer Discov Date: 2013-07-10 Impact factor: 39.397
Authors: Howard I Scher; David Lu; Nicole A Schreiber; Jessica Louw; Ryon P Graf; Hebert A Vargas; Ann Johnson; Adam Jendrisak; Richard Bambury; Daniel Danila; Brigit McLaughlin; Justin Wahl; Stephanie B Greene; Glenn Heller; Dena Marrinucci; Martin Fleisher; Ryan Dittamore Journal: JAMA Oncol Date: 2016-11-01 Impact factor: 31.777
Authors: Minna D Balbas; Michael J Evans; David J Hosfield; John Wongvipat; Vivek K Arora; Philip A Watson; Yu Chen; Geoffrey L Greene; Yang Shen; Charles L Sawyers Journal: Elife Date: 2013-04-09 Impact factor: 8.140
Authors: Howard I Scher; Ryon P Graf; Nicole A Schreiber; Anuradha Jayaram; Eric Winquist; Brigit McLaughlin; David Lu; Martin Fleisher; Sarah Orr; Lori Lowes; Amanda Anderson; Yipeng Wang; Ryan Dittamore; Alison L Allan; Gerhardt Attard; Glenn Heller Journal: JAMA Oncol Date: 2018-09-01 Impact factor: 31.777
Authors: Zhuming Zhang; Peter J Connolly; Luis Trabalón Escolar; Christian Rocaboy; Vineet Pande; Lieven Meerpoel; Heng-Keang Lim; Jonathan R Branch; Janine Ondrus; Ian Hickson; Tammy L Bush; James R Bischoff; Gilles Bignan Journal: ACS Med Chem Lett Date: 2021-06-29 Impact factor: 4.632
Authors: Rana R McKay; Lucia Kwak; Jett P Crowdis; Jamie M Sperger; Shuang G Zhao; Wanling Xie; Lillian Werner; Rosina T Lis; Zhenwei Zhang; Xiao X Wei; Joshua M Lang; Eliezer M Van Allen; Rupal S Bhatt; Evan Y Yu; Peter S Nelson; Glenn J Bubley; R Bruce Montgomery; Mary-Ellen Taplin Journal: Clin Cancer Res Date: 2021-04-13 Impact factor: 12.531
Authors: Jinge Zhao; Shu Ning; Wei Lou; Joy C Yang; Cameron M Armstrong; Alan P Lombard; Leandro S D'Abronzo; Christopher P Evans; Allen C Gao; Chengfei Liu Journal: Mol Cancer Ther Date: 2020-05-19 Impact factor: 6.261